New Biotech Start-up in Dorchester

IES Life Sciences, Inc., a start-up biotech company focused on using interferons to diagnose and treat a wide range of diseases, has established its laboratory and administrative offices on Maryland’s Eastern Shore. According to CEO David Spiegel, the decision follows the firm’s participation in a unique investment program from the Maryland Department of Commerce. “The Biotechnology Investment Incentive Tax Credit, which is designed to attract companies like ours to economically distressed counties in Maryland, represents a great opportunity for our company and our investors. We’re excited by Maryland’s commitment to biotech and look forward to being a cornerstone of the state’s future biotech hub.” IES will be headquartered in the Eastern Shore Innovation Center; its laboratory will be at University of Maryland Eastern Shore in Princess Anne.

“Maryland is proud to have companies like IES putting down roots in our state,” says State Senator Eckardt, who has been an important voice in support of bring biotechnology companies to Maryland. “We believe that investing in start-ups with such great promise represents a win-win for our state and these ambitious entrepreneurs.”

IES is an innovative, precision diagnostic company with a focus on using interferons to detect traditionally hard to diagnose diseases at their earliest stages. Of particular interest are autoimmune diseases such as Lupus, Rheumatoid Arthritis, Crohn’s and Multiple Sclerosis. The company’s technology also has application in early detection of Infectious diseases such as Ebola, Marburg, Lassa-Fever, Measles and Smallpox.

The body’s earliest response to infection/disease is to make cellular proteins called Interferons (“IFNs”). Virtually every disease has its own unique interferon signature . . . similar to a fingerprint. IES has the only patented diagnostic test that can accurately and reliably distinguish between the various IFN subtypes and thereby identify the Interferon Expression Signature for a disease or infection.

IES founders believe that the marketplace will utilize this innovation in several important ways – healthcare providers can more easily diagnose disease; the Pharmaceutical Industry can develop more targeted drug therapy; and the Government can enhance its preparedness to address threats of bioterrorism or viral pandemics that threaten public health.

Further information about IES Life Sciences, Inc. may be found at http://www.iesdiagnostics.com.